Key Highlights: Implications: Zaynich’s approval gives Wockhardt a home-grown differentiated anti‑infective positioned squarely at India’s metallo‑β‑lactamase (MBL) and XDR Gram‑...
Key Highlights: Implications: Obeda gives Dr. Reddy’s a second GLP‑1 foothold in India, but this time in the much bigger day‑to‑day diabetes market, not just injectable semaglutide. Because it ...
Key Highlights: Implications: Triple Hair is turning TH07 into a genuinely global late‑stage asset in male pattern hair loss by running synchronized Phase III trials in Canada and In...
Key Highlights: Implications: Zintrodiazine’s Phase III go‑ahead positions Zydus as a front‑line Indian innovator in a space long dominated by global public–privat...
Key Highlights: Implications: By pairing one of the lowest weekly price points in the GLP‑1 segment (₹325–₹440) with a vial‑plus‑pen strategy, Glenmark is clearly targeting early initiatio...
Key Highlights: Implications: By pricing its once‑weekly semaglutide at around ₹450 per week via a pre‑filled disposable pen, Alkem is positioning one of the lowest‑cost GLP‑1 op...
Key Highlights: Implications: Qdenga’s positive SEC opinion moves India close to its first widely available dengue vaccine, with import approval tied to a rapid post‑marketing s...
Key Highlights: Implications: The new indication firmly positions durvalumab as a frontline immunotherapy option in advanced liver cancer, giving oncologists a more con...
